Stem Cell News

  • Joined meeting of BeSSCR and FSSCR

    Posted on September 8, 2022

    We are pleased to remind you that the 5th Annual Meeting of the French Society for Stem Cell Research (FSSCR) co-organized by the BeSSCR is held from 10 to 11 October 2022 at the "Palais de la Musique et des Congrès" in Strasbourg (France).

    We invite you to visit the congress website in order to register.


  • The research group Reproduction and Genetics (REGE) is hiring postdocs

    Posted on May 24, 2021

    Post-doctoral position in oncogenesis by pluripotent stem cells
    A post-doctoral position is immediately available in the team of Dr. Claudia Spits, at the stem cell lab of the research group Reproduction and Genetics of the Vrije Universiteit Brussel, Belgium. Our lab is focussed on studying genomic instability in human pluripotent stem cells (https://rege.research.vub.be/en/claudia-spits-team), and we are now initiating several projects on the study of the oncogenic potential of aneuploid pluripotent stem cell-derived cells. The successful candidate will develop an organoid-based models for cancer, and test the role of different genetic abnormalities in priming for oncogenic transformation. We offer a fully-funded post-doctoral position, including consumables and travel money, in a highly collaborative and international team. Our research group has brand new lab facilities, state-of-the-art equipment, and a stimulating and ambitious research environment. We are looking for applicants with experience in pluripotent stem cell culture and differentiation, with know-how in organoid culture being a bonus. The applicant should be experienced in high-resolution imaging, such as confocal or light-sheet microscopy, and in massive parallel sequencing-based genome and transcriptome analysis. To apply, please submit a letter with a summary of research interests and experience, your CV, and a list of 3 professional references to Dr. Claudia Spits (claudia.spits@vub.be). More information on: https://jobs.vub.be/job/Jette-Postdoctoral-scientific-researcher-'Stem-cell-biology'/674934401/

    Post-doctoral position in causes of poor development of human embryos and failed implantation
    A postdoctoral position is immediately available in the team of Prof Dr Karen Sermon, at the stem cell lab of the Research Group Reproduction and Genetics of the Vrije Universiteit Brussel, Belgium. Our lab is focused on early human embryology and stem cell biology, in particular the study of genome instability. We are now initiating several projects to study the causes of poor development of human embryos in vitro, as well as implantation failure. The successful candidate will study human embryos through genomics, transcriptomics and imaging, will help develop methods to make synthetic embryos from pluripotent stem cells and models for implantation using endometrial organoids. We offer a fully-funded post-doctoral position, including consumables and travel money, in a highly collaborative and international team. Our research group has brand new lab facilities, state-of-the-art equipment, and a stimulating and ambitious research environment. The applicant should be experienced in embryo manipulation and high-resolution imaging, such as confocal or light-sheet microscopy, and in massive parallel sequencing-based genome and transcriptome analysis. We are also looking for applicants with experience in stem cell biology and organoids. Knowledge of bio-informatics is a bonus. To apply, please submit a letter with a summary of research interests and experience, your CV, and a list of 3 professional references to Dr. Karen Sermon (karen.sermon@vub.be). More information on: https://jobs.vub.be/job/Jette-Postdoc-researcher-'Reproduction-and-genetics%2C-human-embryology%2C-stem-cell-biology'/674314301/

  • Special Issue "Pluripotent Stem Cells for Regenerative Medicine" in Cells

    Posted on July 27, 2020

    Human pluripotent stem cells are slowly but steadily transitioning from bench to bedside, with the first clinical trials showing promising results. Nevertheless, the spectrum of potentially treatable conditions is still limited, and issues such as genome instability and suboptimal differentiation are significant hurdles to the safe transition of these cells to the clinic. This Special Issue welcomes manuscripts providing insight on aspects relevant to the use of hPSC in regenerative medicine. We are interested in a wide range of work, including differentiation to novel cell types or improvement on existing cell types, and their preclinical testing. Work on biomaterials and scaffolding, with an eye for tissue engineering are also key for advanced hPSC-based therapy. Finally, work on safety, such as addressing the tumorigenic potential of hPSC-derived products, and scalability aspects, such as cell culture, are essential for the successful clinical application of these cells. More information can be found on https://www.mdpi.com/journal/cells/special_issues/psc_regenerative_medicine.
    Please contact me if you are interested in submitting a manuscript, I am able to provide you with a personalised invitation to submit, that will include a discount for the publication fee.
    Prof. Dr. Claudia Spits
    Guest Editor

  • From Stem Cell Biology to New Therapies, 6-8 November 2019 in Toronto, Canada

    Posted on August 4, 2019

    The ISSCR will host an international symposium this November in Toronto. The event will attract an international delegation of scientists focusing on clinical application. Join the ISSCR and BlueRock Therapeutics for From Stem Cell Biology to New Therapies, 6-8 November 2019 in Toronto, Canada. As our understanding of stem cell biology surges forward, new and exciting investigational therapies are rapidly advancing towards and through clinical trials. The program will highlight the most current and promising clinical applications of stem cell therapies, feature world-renowned leaders in translational research from academia and industry, and include an interactive panel that will discuss the regulatory challenges of translational stem cell research. View the program and register at www.isscr.org/toronto2019.

  • 3rd Annual BeSSCR meeting in Hasselt

    Posted on juni 6, 2016

    The BeSSCR Board is proud to invite you to the 3rd annual meeting of the BeSSCR which will be held as a joint meeting together with the European Society of Dental & Craniofacial Stem Cells (ESDCSC) in Hasselt on Friday September 16th, 2016.

    Following keynote speakers have already confirmed their presence; we hope that you will do so too:
    Prof. Dr. Ludovic Vallier – Cambridge Stem Cell Institute
    Prof. Dr. Hans-Reimer Rodewald – Heidelberg University Hospital
    Prof. Dr. Anibal Diogenes – University of Texas Health Science Center
    Prof. Dr. Paul Cooper – The University of Birmingham
    Dr. Valérie Wittamer – Université Libre de Bruxelles
    Prof. Dr. Vincent Pasque – Katholieke Universiteit Leuven
    Prof. Dr. Wen-Hui Lien – Université Catholique de Louvain

    With best regards and looking forward to meeting you in Hasselt!
    The BeSSCR Board

  • Stem Cells as Disease Model and for Gene Therapy

    Posted on februari 22, 2016

    Dear colleagues,

    We kindly invite you to the first joint BeSSCR/BSCDB meeting on the use of stem cells as disease model and for gene therapy, on Friday May 27th in Brussels.

    For this meeting, the Belgian Society for Stem Cell Research and the Belgian Society for Cell and Developmental Biology join forces to present you an attractive program including international renowned speakers and several presentation opportunities for PhDs and Post-Docs.

    On the program:
    Dr. Rachel Eiges – Shaare Zedek Medical Center – Jerusalem, IL “Human pluripotent stem cells as a model for DNA repeat instability”
    Dr Bon-Kyoung Koo – Wellcome Trust – MRC Stem Cell Institute – Cambridge, UK “LGR5+ intestinal stem cells and CFTR gene correction in adult stem cells”
    Dr. Thierry VandenDriessche –Vrije Universiteit Brussel “Stem cell-based gene therapy of Duchenne muscular dystrophy”
    Dr. Peter Ponsaerts – Universiteit Antwerpen “IL13-mediated alternative activation of microglia and macrophages in mouse models of neuroinflammation: genetically engineered stem cells versus lentiviral vector gene therapy”

    Looking forward to meeting you in Brussels!